Screening for High Frequency Malignant Disease

Study Summary

The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.

Conditions

Lung Cancer

Interventions / Drugs

Low-dose CT scan

View on ClinicalTrials.gov ↗

Sponsor

Guardant Health

Oncology Diagnostics

D41/100

Study Details

Enrollment12000 participants

Primary Completion—

Lead SponsorGuardant Health, Inc.

Data Retrieved2026-04-11 04:14:36.379915+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.